NOTICE OF MEETING AND AGENDA
Enforcement Committee and E-Pedigree Public Meeting
March 21, 2012

Contact Person: Virginia Herold
(916) 574-7911

This board meeting is open to the public and is accessible to the physically disabled. A person who needs a disability-related accommodation or modification in order to participate in the meeting may make a request by contacting Richard Hultgren at (916) 574-7934, by emailing richard.hultgren@dca.ca.gov or sending a written request to the Board of Pharmacy, 1625 N. Market Blvd., Suite N-219, Sacramento, CA 95834. Providing your request at least five business days before the meeting will help to ensure availability of the requested accommodation.

DATE: March 21, 2012
PLACE: Hilton San Francisco Airport
600 Airport Boulevard
Burlingame, Ca 94010

WEBCAST:  http://www.pharmacy.ca.gov/meetings/current_webcasts.shtml
(link to Webcast will not be available until 9:30 a.m. on March 21, 2012)

Agenda items may be taken out of order to accommodate speakers and to maintain a quorum. The meeting may be cancelled without notice. For verification of the meeting, call (916) 574-7900 or access the Board’s Web site at www.pharmacy.ca.gov.

Discussion and action may be taken on any item on the agenda. An opportunity for public comment is provided for each open agenda item and at the end of each committee’s report. All times are approximate and subject to change. Time limitations for discussion and comment will be determined by the President.

---

**Agenda**

**Wednesday, March 21, 2012**

*Call to Order* 9:30 a.m.

I. **Presentation and Discussion on the Use of Off-Shore Entities to Input Patient Treatment and Refill Authorization for California Pharmacies**
II. Discussion on the Implementation of California’s Electronic Pedigree Requirements for Prescription Medication 10:15 a.m.

a. Discussion about the Presence of Counterfeit Avastin in California Physician Offices

b. Presentation and Discussion of a Proposal for Federal Legislation by the Pharmaceutical Distribution Security Alliance

c. Presentation by Connie T. Jung, RPh, PhD, Acting Associate Director for Policy and Communications, Center for Drug Evaluation and Research, US Food and Drug Administration

d. Presentations and Questions from the Pharmaceutical Supply Chain on Their Readiness to Meet California’s Staggered E-Pedigree Implementation Schedule
1. Kimberly Fleming, Senior Manager, Product Security, EMD Serono, Inc,
2. Robert Celeste, Director, Healthcare, GS1 US
3. Other Companies, Associations and Other Entities Wishing to Address the Committee on E-Pedigree Issues

e. General Discussion

f. Discussion and Possible Action to Develop Regulation Requirements Specifying a Unique Identification Number for Prescription Medication Pursuant to California’s E-Pedigree Requirements

g. Discussion and Possible Action to Develop “Grandfathering” Provisions for Non-Pedigreed Dangerous Drugs Pursuant to section 4163.2 of the Business and Professions

h. Closing Comments

III. Public Comment on Items Not on the Agenda/Agenda Items For Future Meetings

Note: The committee may not discuss or take action on any matter raised during this public comment section that is not included on this agenda, except to decide whether to place the matter on the agenda of a future meeting. [Government Code Sections 11125, 11125.7(a)]

ADJOURNMENT 4 p.m.